Literature DB >> 25165555

Erythromycin, QTc interval prolongation, and torsade de pointes: Case reports, major risk factors and illness severity.

Jules C Hancox, Mehrul Hasnain1, W Victor R Vieweg2, Michael Gysel3, Michelle Methot4, Adrian Baranchuk3.   

Abstract

OBJECTIVES: Erythromycin is a macrolide antibiotic that is widely used for various infections of the upper respiratory tract, skin, and soft tissue. Similar to other macrolides (clarithromycin, azithromycin), erythromycin has been linked to QTc interval prolongation and torsade de pointes (TdP) arrhythmia. We sought to identify factors that link to erythromycin-induced/associated QTc interval prolongation and TdP. METHODS AND
RESULTS: In a critical evaluation of case reports, we found 29 cases: 22 women and 7 men (age range 18-95 years). With both oral and intravenous erythromycin administration, there was no significant relationship between dose and QTc interval duration in these cases. Notably, all patients had severe illness. Other risk factors included female sex, older age, presence of heart disease, concomitant administration of either other QTc prolonging drugs or agents that were substrates for or inhibitors of CYP3A4. Most patients had at least two risk factors.
CONCLUSIONS: On the basis of case report evaluation, we believe that major risk factors for erythromycin-associated TdP are female sex, heart disease and old age, particularly against a background of severe illness. Coadministration of erythromycin with other drugs that inhibit or are metabolized by CYP3A4 or with QTc prolonging drugs should be avoided in this setting.

Entities:  

Keywords:  drug-induced QTc interval prolongation; erythromycin; risk factors; torsade de pointes

Year:  2014        PMID: 25165555      PMCID: PMC4072045          DOI: 10.1177/2049936114527744

Source DB:  PubMed          Journal:  Ther Adv Infect Dis        ISSN: 2049-9361


  68 in total

Review 1.  The QT interval.

Authors:  M M Bednar; E P Harrigan; R J Anziano; A J Camm; J N Ruskin
Journal:  Prog Cardiovasc Dis       Date:  2001 Mar-Apr       Impact factor: 8.194

2.  Torsades de pointes associated with nonantiarrhythmic drugs and observations on gender and QTc.

Authors:  Martin M Bednar; Edmund P Harrigan; Jeremy N Ruskin
Journal:  Am J Cardiol       Date:  2002-06-01       Impact factor: 2.778

3.  Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern.

Authors:  Glenn E Kirsch; Elena S Trepakova; Jessica C Brimecombe; Serguei S Sidach; Hope D Erickson; Mary C Kochan; Lisa M Shyjka; Antonio E Lacerda; Arthur M Brown
Journal:  J Pharmacol Toxicol Methods       Date:  2004 Sep-Oct       Impact factor: 1.950

4.  Azithromycin and the risk of cardiovascular death.

Authors:  Wayne A Ray; Katherine T Murray; Kathi Hall; Patrick G Arbogast; C Michael Stein
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

5.  A review of erythromycin-induced malignant tachyarrhythmia--torsade de pointes. A case report.

Authors:  K Katapadi; G Kostandy; M Katapadi; K M Hussain; D Schifter
Journal:  Angiology       Date:  1997-09       Impact factor: 3.619

6.  Synergic effects of β-estradiol and erythromycin on hERG currents.

Authors:  Fumiaki Ando; Akinori Kuruma; Seiko Kawano
Journal:  J Membr Biol       Date:  2011-04-12       Impact factor: 1.843

Review 7.  Drug-induced long QT and torsade de pointes: recent advances.

Authors:  Prince J Kannankeril; Dan M Roden
Journal:  Curr Opin Cardiol       Date:  2007-01       Impact factor: 2.161

8.  Drug-induced torsades de pointes: a possible interaction of terfenadine and erythromycin.

Authors:  K E Biglin; M S Faraon; T D Constance; M Lieh-Lai
Journal:  Ann Pharmacother       Date:  1994-02       Impact factor: 3.154

Review 9.  Erythromycin induced Torsades de Pointes: case report and review of the literature.

Authors:  M A Rezkalla; C Pochop
Journal:  S D J Med       Date:  1994-05

10.  Clarithromycin, QTc interval prolongation and torsades de pointes: the need to study case reports.

Authors:  W Victor R Vieweg; Jules C Hancox; Mehrul Hasnain; Jayanthi N Koneru; Michael Gysel; Adrian Baranchuk
Journal:  Ther Adv Infect Dis       Date:  2013-08
View more
  5 in total

1.  Macrolide antibiotics and the risk of ventricular arrhythmia in older adults.

Authors:  Mai H Trac; Eric McArthur; Racquel Jandoc; Stephanie N Dixon; Danielle M Nash; Daniel G Hackam; Amit X Garg
Journal:  CMAJ       Date:  2016-02-22       Impact factor: 8.262

2.  Overall safety of relamorelin in adults with diabetic gastroparesis: Analysis of phase 2a and 2b trial data.

Authors:  Michael Camilleri; Anthony Lembo; Richard McCallum; Stavros Tourkodimitris; Lara Kemps; Matthew B Miller; Kirk Bertelsen; Alexandru Iacob
Journal:  Aliment Pharmacol Ther       Date:  2020-04-17       Impact factor: 8.171

Review 3.  Humans Vary, So Cardiac Models Should Account for That Too!

Authors:  Barbara Wiśniowska; Zofia Tylutki; Sebastian Polak
Journal:  Front Physiol       Date:  2017-09-21       Impact factor: 4.566

4.  The macrolide drug erythromycin does not protect the hERG channel from inhibition by thioridazine and terfenadine.

Authors:  Aziza El Harchi; Andrew S Butler; Yihong Zhang; Christopher E Dempsey; Jules C Hancox
Journal:  Physiol Rep       Date:  2020-03

5.  Dynamics of the QTc interval over a 24-h dose interval after start of intravenous ciprofloxacin or low-dose erythromycin administration in ICU patients.

Authors:  Florine A Berger; Willem van Weteringen; Heleen van der Sijs; Nicole G M Hunfeld; Jeroen J H Bunge; Natasja M S de Groot; Patricia M L A van den Bemt; Teun van Gelder
Journal:  Pharmacol Res Perspect       Date:  2021-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.